title: Immunohistochemical profile of ductal adenocarcinoma of the prostate.
abstract: Ductal adenocarcinoma of the prostate (DAC) is considered to be an aggressive subtype of prostate cancer with greater risk of progression than acinar adenocarcinoma (AC). It has been debated whether DAC is a distinct subtype or a morphological variant of AC. Our aim was to examine the protein expression of DAC and to compare the results with AC. A tissue microarray was constructed from 60 DAC and 46 AC matched by Gleason score. The slides were stained for 28 immunomarkers (estrogen, progesterone and androgen receptor, prolactin, PSA, prostein, PSMA, PSAP, CDX2, lysozyme, villin, monoclonal CEA, CK7, CK20, HMWCK, p63, p504s, c-myc, EGFR, Ki-67, p16, p21, p27, p53, PTEN, ERG, PAX-2, and PAX-8). HMWCK was positive in 8.5 % of DAC, but negative in all cases of AC (p = 0.045). p16 was positive in 53.3 % of DAC and in 26.1 % of AC (p = 0.005). p53 was positive in 42.4 % of DAC and 26.7 % of AC (p = 0.031). A distinct patchy positivity of CK20 was seen in 23.7 % of DAC, and this pattern was also seen in 9.1 % of AC (p = 0.047). Villin was positive in 3.4 % of DAC while expression was negative in AC. Ki-67 labeling index was significantly higher in DAC than in AC (mean 9.2 % [95 % CI 6.4-12.0] and 2.6 % [1.9-3.4], p < 0.001). While there is some overlap in the immunohistochemical expression of DAC and AC, the differences between these two morphotypes of prostatic carcinoma are consistent with DAC having a more aggressive phenotype than AC.
authors: Department of Oncology-Pathology, Karolinska Institutet, Radiumhemmet P1:02, Karolinska University Hospital, 171 76, Stockholm, Sweden.
authors: Amanda H
authors: AH
authors: Seipel
authors: Hemamali
authors: H
authors: Samaratunga
authors: Brett
authors: B
authors: Delahunt
authors: Fredrik
authors: F
authors: Wiklund
authors: Peter
authors: P
authors: Wiklund
authors: Johan
authors: J
authors: Lindberg
authors: Henrik
authors: H
authors: Grönberg
authors: Lars
authors: L
authors: Egevad
mesh_terms: D000230:Adenocarcinoma / Q000473:pathology* / Q000503:physiopathology; D014408:Biomarkers, Tumor; D018267:Carcinoma, Acinar Cell / Q000473:pathology / Q000503:physiopathology; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000096:biosynthesis; D006801:Humans; D007150:Immunohistochemistry; D019394:Ki-67 Antigen / Q000096:biosynthesis; D008297:Male; D011467:Prostate / Q000473:pathology; D011471:Prostatic Neoplasms / Q000473:pathology* / Q000503:physiopathology; D040081:Protein Array Analysis; D016159:Tumor Suppressor Protein p53 / Q000096:biosynthesis
chemical_list: D014408:Biomarkers, Tumor; D019941:Cyclin-Dependent Kinase Inhibitor p16; D019394:Ki-67 Antigen; D016159:Tumor Suppressor Protein p53